AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02192242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acute ischemic pain
Description: acute ischemic pain was induced by treadmill exercise
Study NCT03428698 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aminogam
Description: A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
Study NCT03428698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aminogam
Description: A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
Study NCT03248505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Description: Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
Study NCT03248505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst TENS
Description: Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
Study NCT03248505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 1,5 Kg of crushed ice pack on lumbar spine.
Study NCT03248505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst TENS + Cryotherapy
Description: Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
Study NCT03248505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional TENS + Cryotherapy
Description: Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
Study NCT03248505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: TENS device turned on, but with zero amplitude.
Study NCT00920972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Plan 1: Stratum 1
Description: Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
Study NCT00920972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Plan 2: Strata 2, 3, or 4
Description: Day -50 to -21: Hydroxyurea 30mg/kg PO q day... Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
Study NCT00920972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Regimen A: UCB Recipients
Description: Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
Study NCT00920972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Regimen B: BM Recipients
Description: Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
Study NCT01343459 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HIOB
Description: IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy
Study NCT03951805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered subcutaneously SC once weekly. Starting dose will be 70U.
Study NCT03951805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered subcutaneously SC once daily.The starting dose will be 10U.
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: 1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
Study NCT01660230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl in water
Study NCT00742131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089
Description: GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
Study NCT00472654 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Loss
Description: Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
Study NCT00472654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
Study NCT00472654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 2500 IU
Description: Daily Vitamin D 2500 IU supplement for 6 weeks
Study NCT00472654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 2500 IU
Description: Daily Vitamin D 2500 IU supplement for 6 weeks
Study NCT00472654 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Maintenance
Description: Diet for weight maintenance for 6 weeks
Study NCT00472654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Diet for weight maintenance for 6 weeks
Study NCT00586716 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immune globulin
Description: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
Study NCT01268540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FY-60AD
Description: Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
Study NCT01268540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHT15, NHT30, & NHT53
Description: Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
Study NCT02243371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: 1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
Study NCT02243371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: 1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
Study NCT02243371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 3 mg/kg administered IV on Day 1 of Cycles 1-6
Study NCT02243371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
Study NCT02243371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
Study NCT01995500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNIR
Description: drug-eluting stent
Study NCT01995500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute
Description: drug-eluting stent
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL101
Description: Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL101
Description: Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral administration started by 6 days post-transplantation and continued for 6 months
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral administration started by 6 days post-transplantation and continued for 6 months
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Oral administration started by Day 1 post-transplantation and continued for 6 months
Study NCT01154387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Oral administration started by Day 1 post-transplantation and continued for 6 months
Study NCT04320056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard administration of oxygen flow
Description: The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode
Study NCT04320056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen administration - FreeO2
Description: In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
Study NCT00566553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 200 mg dose daily for 12 weeks.
Study NCT00566553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 400 mg dose daily for 12 weeks.
Study NCT00566553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 600 mg dose daily for 12 weeks.
Study NCT00566553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 800 mg dose daily for 12 weeks.
Study NCT04084405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
Study NCT04084405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
Study NCT04018157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and dexmedetomidine and propofol and 0.9%saline
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
Study NCT04018157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine and dexmedetomidine and propofol and 0.9%saline
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
Study NCT04030949 — intervention group
Intervention type: OTHER
Intervention: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Description: No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
Study NCT03432767 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive hemoglobin monitor
Study NCT02279563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray
Description: During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days
Study NCT02279563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista™ Nasal Spray
Study NCT02279563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03143413 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography
Description: Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.
Study NCT04394286 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SHP648
Description: Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
Study NCT04390191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
Study NCT01500161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
Study NCT03365492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ BA9™ drug-coated stent
Description: Drug-coated stent for coronary arteries
Study NCT02321878 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given.
Study NCT03800329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Snap40 Monitor
Description: Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
Study NCT03800329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Monitor
Description: Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
Study NCT01867437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution (vehicle) for subcutaneous infusion
Study NCT01867437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-493
Description: Sterile solution (2mg/ml) for subcutaneous infusion
Study NCT03349580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The training group
Description: The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
Study NCT04011319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group culture
Description: Four embryos were cultured in the same droplet by a special dish.
Study NCT02865265 — intervention group
Intervention type: PROCEDURE
Intervention: Pecs II and parasternal blocks
Description: Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib.
Study NCT01176240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
Study NCT01176240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02053519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Vigantol Oil (Vitamin D3)
Description: Vitamin D Oral oil 100.000iu in 5 mls
Study NCT02053519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mygliol Oil
Description: Matched placebo comparator
Study NCT04191213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Senegal extract
Description: Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
Study NCT04191213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pectin
Description: Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
Study NCT02274415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with the combined vaccine (Prevenar13 ®)
Study NCT02274415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
Study NCT02274415 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
Study NCT02205164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron + Aprepitant
Description: Aloxi 0.25mg Emend 125/80/80 mg
Study NCT02205164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Aloxi 0.25mg